ReviewAmerican journal of translational research2025
Serum levels of Galectin-1 and Galectin-3 for monitoring rheumatoid arthritis severity: a meta-analysis.
Review in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGalectin-1 (Gal-1) and galectin-3 (Gal-3) have emerged as promising biomarkers for diagnosing and managing rheumatoid arthritis (RA). This study aims to synthesize current evidence through a systematic review and meta-analysis to evaluate the clinical effectiveness of serum Gal-1 and Gal-3 as biomarkers for monitoring disease severity and predicting clinical outcomes in RA patients.
methodsWe conducted a comprehensive literature search in PubMed, Web of Science, and the Cochrane Library, including studies published up to March 2024. Eleven observational studies were selected based on predefined inclusion criteria. The risk of bias in these studies was assessed using the Cochrane Handbook for Systematic Reviews of Interventions. Data synthesis and meta-analysis were performed using RevMan 5.3 software, with the study protocol registered at INPLASY (ID: 202460103).
resultsThe meta-analysis included 1213 participants (comprising 809 RA patients and 404 healthy controls) from 11 studies. Serum levels of Gal-1 and Gal-3 were significantly higher in RA patients compared to controls (MD=25.09 ng/ml, 95% CI: 24.18-26.00 ng/ml, P<0.00001; MD=30.51 ng/ml, 95% CI: 29.10-31.93 ng/ml, P<0.00001). Moreover, Gal-1 levels exhibited a positive correlation with RA disease activity markers, such as the Erythrocyte Sedimentation Rate (ESR) and the Disease Activity Score 28 (DAS28). The analysis demonstrated a correlation coefficient of r=0.24 (95% CI: 0.14-0.33, P<0.00001) between Gal-1 and RA disease activity, highlighting a notable association. Similarly, Gal-3 showed significant positive correlations with ESR (r=0.29, 95% CI: 0.18-0.40, P<0.00001), DAS28 (r=0.25, 95% CI: 0.13-0.37, P<0.00001), and C-reactive protein (CRP) (r=0.15, 95% CI: 0.05-0.26, P<0.00001). The overall correlation between circulating Gal-3 levels and RA disease severity indices was r=0.23 (95% CI: 0.16-0.29, P<0.00001).
conclusionGal-1 demonstrates significant potential as a biomarker for diagnosing and managing RA. Monitoring Gal-1 and Gal-3 levels may provide valuable insights into early disease assessment and progression, potentially improving treatment outcomes for RA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.